











































Atherosclerosis is a chronic inflammatory disease that 
develops over decades leading to the clinical events of 
cardiovascular disease such as heart attacks and strokes. 
Atherosclerosis commences with the trapping of 
lipoproteins in the vessel wall by modified 
proteoglycans [1, 2] followed by disruption and 
dysfunction of the vascular endothelium and then a 
complex inflammatory reaction involving multiple 
immune cells some of which promote  the  development  
 
 










































of the atherosclerotic plaques [3-5]. Plaques can be 
stable or labile where the latter are those that rupture to 
precipitate the life threatening clinical events [6]. 
Besides current cholesterol lowering therapy for the 
treatment of atherosclerosis, preferable therapies that 
address the disease process in the vessel wall are 
needed. One such potential strategy is to correct 
endothelial dysfunction, which is evidenced by 
impaired endothelium-dependent vasorelaxation, up-
regulation of adhesion molecules and increased 
leukocyte adhesion and invasion, eventually resulting in 























well  understood.  Here  we  show  that  SIRT6  protects  against  endothelial  dysfunction  and  atherosclerosis.  Global  and
endothelium‐specific SIRT6 knockout mice exhibited impaired endothelium‐dependent vasorelaxation. Moreover, SIRT6+/‐
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the formation of a fatty streak, a prominent feature of 
atherosclerosis [7].  
 
Sirtuins (SIRT1-SIRT7) belong to a family of NAD-
dependent deacetylases that are involved in multiple 
cardiovascular pathologies [8-10]. Emerging evidence 
suggests that SIRT6, as a unique chromatin-associated 
deacetylase, share some of SIRT1-mediated protective 
effects [9, 11-15], such as inhibiting heart failure [16] 
and decelerating aging process [17] in mice. SIRT6 also 
halts endothelial inflammation [18], aging [19-21], as 
well as regulates dendritic cell differentiation, 
maturation and function [22]. In addition, SIRT6 
expression is decreased in endothelial cells (ECs) under 
chronic stimulation with lipopolysaccharide (LPS) [18], 
hydrogen peroxide (H2O2) [21] and high glucose [23-
25], three of which are risk factors associated with 
endothelial dysfunction and atherogenesis. More 
recently, SIRT6 expression was reported to decrease in 
atherosclerotic ApoE-/- mice [26, 27] and human 
patients [23, 27]. Moreover, SIRT6 genetic variants 
(rs107251, rs352493 and rs3760908) have been 
































disease (CAD) [28, 29]. Therefore, further 
understanding of the atheroprotective role of SIRT6 
would facilitate the translational exploitation of SIRT6 
based therapeutic approaches in treating CAD. 
 
In this report, we aim to address the role of SIRT6 in 
regulating endothelial dysfunction and atherosclerosis in 




Global deletion of SIRT6 impairs endothelium-
dependent vasorelaxation 
 
We first characterized the expression of SIRT6 in 
murine tissues. We found that in normal C57BL/6J 
mice, SIRT6 gene was ubiquitously expressed in murine 
heart, lung, liver, kidney, aorta, skeletal muscle, spleen 
and brain (Figure S1). Noticeably, SIRT6 is highly 
expressed in EC-enriched tissues, such as lung, aorta 
and brain. The enrichment of SIRT6 in EC-containing 
tissues prompts us to investigate the role of SIRT6 in 
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To test whether SIRT6 deficiency in mice induces 
endothelial dysfunction, experiments were performed 
on SIRT6 global knock-out (SIRT6-/-) mice. These mice 
were obtained by crossing female SIRT6flox/flox mice 
[30] and male EIIa-Cre mice [31], which carry a Cre 
transgene under the control of the EIIa promoter that 
targets expression of Cre recombinase to the early 
mouse embryo and are useful for germ line deletion of 
loxP-flanked genes (Figure. 1A). Consistent with 
previous reports [11, 30], we found that SIRT6-/- mice 
had lower body weight at 3-4 weeks of age (Figure S2) 
as well 12-weeks of age (Table S1) and most SIRT6-/- 
mice die shortly after weaning. In survived SIRT6-/- 
adult mice, we observed that, as compared to SIRT6+/+ 
littermates, SIRT6-/- mice (Fig. S3A) had lower arterial 
systolic blood pressure and heart rate (Table S1), which 
may occur due to the complex phenotypes of SIRT6-/- 
mice [11]. Western blot analysis showed that aortic 
SIRT6 protein was reduced by 42 % and 91% in 
SIRT6+/- mice and SIRT6-/- mice, respectively (Figure 
1B). Endothelium-dependent vasorelaxation to 
acetylcholine (Ach) was significantly impaired in 

































(Figure 1C). In contrast, endothelium-independent 
relaxation to sodium nitroprusside (SNP) did not differ 
significantly between SIRT6+/+ and SIRT6-/- aortae 
(Figure 1D). However, SIRT6 haploinsufficiency in 
mice (SIRT6+/-) shows similar Ach-induced 
endothelium-dependent vasorelaxation as well as SNP-
induced endothelium-independent vasorelaxation under 
normal chow diet feeding conditions (Figure 1C and 
1D).  
 
Endothelium-specific deletion of SIRT6 impairs 
endothelium-dependent vasorelaxation 
 
To ask whether endothelial SIRT6 regulates Ach-
induced vasorelaxation, we generated endothelial cell-
specific SIRT6 knockout (ecSIRT6-/-) mice and 
analyzed vasorelaxation of aortas from those mice. To 
this end, male Tie2-Cre mice [32] were cross-bred with 
SIRT6flox/flox [30] female mice to generate male Tie2-
Cre; SIRT6flox/+ mice, which were further intercrossed 
with SIRT6flox/flox females to obtain endothelium-
specific SIRT6 knockout animals (ecSIRT6-/-, Figure 




































by Western blotting, n=4.  (C) Reactivity of ecSIRT6+/+ and ecSIRT6‐/‐ aortic rings  to acetylcholine  (Ach), ***P<0.001, compared  to
ecSirt6+/+ littermates, n = 9; (D) Reactivity of ecSIRT6+/+ and ecSIRT6‐/‐ aortic rings to sodium nitroprusside (SNP), n = 10.  
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revealed a close normal Mendelian frequency for 
ecSIRT6-/- mice (Table S2). The ecSIRT6-/- mice were 
viable and normal in size and did not display obvious 
physical, behavioral or reproductive abnormalities 
compared with littermate controls (SIRT6flox/flox). In 
addition, the ecSIRT6-/- mice were normotensive and 
had a normal heart rate (Table S1). To confirm the 
endothelium-specific SIRT6 deletion in these ecSIRT6-/- 
mice, Western blot analysis was performed. SIRT6 
protein expression was significantly decreased in 
intimal EC lysate from ecSIRT6-/- aortae (Figure 2B). 
Subsequently, the effect of endothelial SIRT6 deletion 
on vascular reactivity was examined. We found that the 
concentration-dependent, Ach-induced vasorelaxation 
was significantly reduced in aortae of ecSIRT6-/- mice 
compared with ecSIRT6+/+ (SIRT6flox/flox) control 
preparations (Figure 2C). By contrast, relaxations to 
SNP did not differ between ecSIRT6+/+ and ecSIRT6-/- 
mice (Figure 2D). Taken together, these results indicate 
that endothelial SIRT6 is critical for the maintenance of 
normal endothelium-dependent vasorelaxation.  
 
SIRT6 haploinsufficiency impairs endothelium-
dependent vasorelaxation in mice fed a high fat diet 
(HFD) 
 
To further investigate whether SIRT6 haploin-
sufficiency aggravates endothelial dysfunction under 
HFD feeding conditions, we challenged SIRT6+/- mice 
and WT mice with a HFD for 3 months. We found that 
Ach-induced, endothelium-dependent vasodilation was 























SIRT6+/+ littermates (Figure 3A). However, the 
relaxation of the aortic rings in response to SNP in both 
genotypes of mice was similar (Figure 3B). These 
results indicate that SIRT6 haploinsufficiency 
aggravates endothelial dysfunction in vivo under hyper-
cholesterolaemic dietary conditions. 
 
SIRT6 haploinsufficiency exacerbates the 
development of atherosclerosis in ApoE-/- mice 
 
Impaired endothelium-dependent vasorelaxation is a 
hallmark of early phase of atherosclerosis. Thus, we 
hypothesized that SIRT6 protects against the 
development of atherosclerosis in mice. To test this 
hypothesis, SIRT6+/- mice were bred with ApoE−/− 
mice to obtain SIRT6+/-; ApoE−/− mice (Figure 4A). 
Male SIRT6+/-; ApoE−/− mice and their littermate 
controls male SIRT6+/+; ApoE−/− mice at 8-weeks of 
age were put on a HFD for 8 additional weeks to 
accelerate atherosclerosis development. At the end of 
HFD feeding, mice were euthanized, and 
atherosclerosis lesion formation in aorta and aortic 
sinus were analyzed by en face analysis of the whole 
aorta and by cross-sectional analysis of the aortic 
sinus. Our data showed that SIRT6+/-;ApoE−/− mice 
had more atherosclerotic plaques in the aorta (Figure 
4B and 4C, P < 0.05) and the aortic sinus (Figure 4D 
and 4E, P < 0.01) than those in SIRT6+/+; ApoE−/− 
control mice. Analysis of lipid profile suggests that 
SIRT6 haploinsufficiency significantly increased 
serum HDL levels without affecting TG and 






































































SIRT6 haploinsufficiency increases the expression of 
adhesion molecule VCAM-1 in ApoE-/- mice 
 
Endothelial cell adhesion molecules, such as vascular 
cell adhesion molecule-1 (VCAM-1), play an important 
role in atherogenesis by promoting monocyte adhesion 
to inflamed endothelium [7, 45]. Thus we examined the 
effect of SIRT6 deletion on VCAM-1 expression in 
aortic sinus. We observed that VCAM-1 was increased 
in atherosclerotic plaques of SIRT6+/-; ApoE-/- 
compared with SIRT6+/+; ApoE-/- mice (Figure 5). 
These results indicate that SIRT6 prevents adhesion 
molecule VCAM-1 expression. 
 
SIRT6 inhibits monocyte adhesion to endothelial cells 
 







































SIRT6-mediated atheroprotection, we evaluated the 
effect of loss- and gain-of SIRT6 function on tumor 
necrosis factor alpha (TNF-α)-induced monocyte 
adhesion to ECs. HUVECs were transfected with SIRT6 
siRNA for 48 h, or infected with SIRT6 adenovirus (the 
multiplicity of infection or M.O.I. 10) for 24 h (Figure 
S4). We then evaluated the effect of SIRT6 depletion 
and overexpression on monocyte adhesion to ECs. As 
shown in Figure 6A-D, the number of adhering human 
THP-1 monocytes to HUVECs was significantly 
increased (by 30%, P<0.01) by SIRT6 siRNA treatment 
and decreased (by 50%, P<0.001) by SIRT6 
overexpression. Further studies of the mechanisms 
whereby SIRT6 inhibits monocyte adhesion showed 
that SIRT6 inhibited monocyte adhesion by decreasing 






524  bp  and  390  bp,  respectively.  ApoE‐(Δ),  ApoE+(WT)  bands  appear  at  245  bp  and  155  bp,  respectively.  (B)  SIRT6+/‐/ApoE‐/‐
developed more atherosclerotic plaques  in en face aorta. SIRT6+/‐/ApoE‐/‐ and SIRT6+/+/ApoE−/− mice were fed HFD for 8 weeks.
The mice were  then  sacrificed  and  aortas  from  the  aortic  arch  to  the  iliac  arteries were  examined  for  atherosclerotic  lesion




















































































































Figure 5. SIRT6 deficiency  increases VCAM‐1 expression  in ApoE‐/‐ mice. Aortic  sinus  from  SIRT6+/+; ApoE‐/‐  and  SIRT6+/‐;
ApoE‐/‐ mice were stained with VCAM‐1 (red) antibody. DAPI was used to counterstain cell nuclei, bar=30 um, n=4‐6/each genotype.  
 
Figure 6. SIRT6  inhibits monocyte adhesion  to endothelial  cells by attenuating VCAM‐1.  (A‐B) HUVECs  transfected
with SIRT6 siRNA (48 h, A) or infected with SIRT6 adenovirus (10 M.O.I., 24 h, B), and then monocyte adhesion to endothelial cells
was determined. The representative images were shown after Image J adjustment of the threshold to label adhered monocytes
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SIRT6 overexpression alters endothelial 
transcriptional profile 
 
To gain mechanistic insights into the effects of SIRT6 
on endothelial gene transcriptome, we performed RNA-
sequencing (RNA-seq) analysis of control adenovirus 

















































(GO), pathway enrichment and functional annotation 
clustering analysis were performed to classify 
differentially expressed genes and to identify the most 
significantly enriched GO terms/pathways/gene 
clusters. RNA-seq data showed that SIRT6 
overexpression in HUVECs significantly downegulated 


















































cells.  (A‐B) Molecular Function Gene Ontology  (GO) and pathway enrichment analysis of  the 198 genes  that were downregulated by
SIRT6 overexpression, determined by RNA‐seq, n=2/each condition. The lists of genes were analyzed using Enrichr database, based on the
combined score ranking. The brighter the color, the more significantly enriched GO term and pathway displayed. Please refer to Table S4
and  S5  for  complete  list  of  gene  change.  (C)  DAVID  functional  annotation  clustering  analysis  of  genes  downregulated  by  SIRT6
overexpression. (D) Selected atherosclerosis‐related genes downregulated by SIRT6 overexpression (OE) detected by RNA‐seq analysis.  
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Overrepresentation analysis of these genes using 
Enrichr database [33] revealed that the top three 
significantly overrepresented molecular function GO 
terms were cytokine and TNF-α receptor (superfamily) 
binding (Figure 7A). PANTHER pathway analysis 
suggests that SIRT6 modulates several important 
pathways in ECs, including angiogenesis, TGF-β 
signaling and integrin signaling (Figure 7B). To 
investigate the enrichment of functional annotation, we 
used Database for Annotation, Visualization and 
Integrated Discovery (DAVID) [34] to examine the 198 
genes downregulated by SIRT6 overexpression. The 
functional annotation clustering results suggests that the 
top two DAVID-defined clusters which displayed 
enrichment scores (ES) >3 under high classification 
stringency parameters were: TNF-α receptor (super-
family) binding and cell death (Figure 7C). Detailed 
analysis of RNA-seq data indicated that SIRT6 
overexpression decreased the expression of multiple 
genes involved in vascular inflammation and 
atherosclerosis, including PTX3 (Pentraxin 3) [35], 
GJA1 (gap junction A1, also known as Connexin 43) 
[36], and TNFSF4 (tumor necrosis factor superfamily 
member 4, also known as OX40 ligand) [37] (Figure 7D 
and Table S4). In addition, SIRT6 overexpression 
upregulates several heat shock protein (HSP) genes that 




























(Heat shock 70 kDa protein 1, also termed Hsp72), 
HSPA1B, and HSPA6 (Table S5).  
 
SIRT6 decreases atherosusceptible gene TNFSF4 by 
deacetylating H3K9 at gene promoter 
 
SIRT6 exerts its activity by deacetylating H3K9 [38, 39], 
H3K18 [40] and H3K56 [41, 42] at gene promoters. 
Particularly, SIRT6 attenuates NF-ƙB signaling by 
deacetylating H3K9 in the promoter region of NF-ƙB 
target genes including VCAM-1 [39]. To further validate 
whether TNFSF4,  a critical atherosusceptible gene [37] 
associating with NF-ƙB pathway [43], is regulated by 
SIRT6, we performed chromatin immunoprecipitation 
(ChIP) assay. Our results indicate that SIRT6 binds to 
promoter region of TNFSF4 under basal conditions 
(Figure 8A), which was increased upon infection with 
SIRT6 adenovirus. However, the level of H3K9Ac 
binding to the TNFSF4 promoter region was significantly 
decreased by SIRT6 overexpression (Figure 8B). We 
next assessed mRNA expression of TNFSF4 in the 
presence or absence of TNF-α treatment. Real-time PCR 
analysis revealed that SIRT6 overexpression significantly 
reduced TNFSF4 expression under basal conditions and 
TNF-α stimulation (Figure 8C). These data suggest that 
SIRT6 decreases TNFSF4 expression by deacetylating 
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DISCUSSION 
 
 Atherosclerosis is a progressive, chronic inflammatory 
and immune disease, which underlies a high incidence 
of cardiovascular morbidity and mortality [7, 44-46]. 
Endothelial dysfunction followed by leukocyte 
infiltration leads to atherosclerotic plaque formation [7]. 
However the molecular mechanisms underlying 
endothelial dysfunction and atherogenesis remain 
incompletely understood. SIRT6 is a chromatin-
associated histone deacetylase [12] highly expressed in 
vascular ECs from different vascular beds [18, 19], and 
SIRT6 represses endothelial inflammation [18] and 
aging [19-21]. However, the role of SIRT6 in regulating 
endothelial function and atherosclerosis remains poorly 
defined. The principal finding of the present study is 
that we demonstrate that SIRT6 reduces atherosclerotic 
lesion formation in a murine model of atherosclerosis 
through attenuating endothelial dysfunction and 
vascular inflammation. 
 
Sirtuins are critical mediators of longevity induced by 
calorie restriction (CR) and CR-mimetic compounds such 
as resveratrol [9, 47]. Mounting evidence suggests that 
sirtuins regulates multiple cellular processes including 
lifespan extension, cellular metabolism and DNA damage 
repair [9, 47-50]. To date, SIRT1 is the best-characterized 
sirtuin in the cardiovascular system [8, 48, 49]. A large 
body of evidence shows that SIRT1 protects against 
atherosclerosis [48, 51-54] through multiple mechanisms, 
such as improving endothelial function [53, 55], 
inhibiting macrophage-derived foam cell formation [56], 
impeding the proliferation, migration [57] and DNA-
damage associated apoptosis [58] of smooth muscle cells 
(SMCs), as well as suppressing thrombosis [59]. More 
recently, SIRT1 activating compound SRT3025 was 
shown to protect against atherosclerosis by modulating 
LDL-degrading enzyme proprotein convertase 
subtilisin/kexin type 9 (PCSK9) in LDLr-/- mice [60]. 
However, there is limited information available regarding 
the role of other sirtuin family members in 
atherosclerosis. SIRT3 provides protection against 
cardiac hypertrophy, dyslipidaemia and cardiomyopathy 
[8], however, genetic ablation of SIRT3 have no impact 
on atherogenesis [61], suggesting distinctive effects of 
different sirtuins in atherosclerosis. In this study, we 
observed that global or endothelium-specific deficiency 
of SIRT6 impaired endothelium-dependent 
vasorelaxation. Because most of SIRT6 knockout mice 
die at 4 weeks of age [11], we used SIRT6 heterozygous 
(SIRT6+/-) mice to study whether SIRT6 haploin-
sufficiency affects endothelium-dependent vasorelaxation 
and atherosclerosis. We observed that under normal diet 
conditions, no significant difference in vascular reactivity 
between aortas from SIRT6+/- mice and wild type mice. 
However, under high-fat diet conditions, SIRT6 
haploinsufficiency impaired endothelium-dependent 
vasorelaxation. We then generated SIRT6+/-; ApoE-/- mice 
and fed them with HFD, and we found that those mice 
had increased atherosclerotic plaque formation. 
Mechanistically, SIRT6 diminishes monocyte adhesion 
by inhibiting the expression of adhesion molecules 
VCAM-1 in cultured ECs. 
 
The development of atherosclerosis is a complex and 
multi-factorial process which involves the alteration of 
vascular endothelium hemostasis [62]. Many factors, 
such as impaired vasorelaxation, leukocyte adherence 
and extravasation, chronic inflammation, oxidative 
stress and aging cause endothelial dysfunction [62]. It 
has been shown that, in cultured ECs, SIRT6 negatively 
regulates EC aging [19, 21] and inflammation [18], 
suggesting that SIRT6 could be a vasculoprotective 
molecule in maintaining endothelial homeostasis. 
However, whether SIRT6 can improve vasorelaxation 
and inhibits monocyte adhesion remain unknown. Our 
gain- and loss-of-function studies in cultured ECs 
showed that SIRT6 inhibited TNF-α-induced monocyte 
adhesion to ECs. Two previous studies suggested that 
SIRT6 siRNA alone increases basal ICAM-1 expression 
[19, 26]. We observed that VCAM-1 expression were 
upregulated in SIRT6-depleted HUVECs in response to 
TNF-α stimulation. Conversely, TNF-α-induced 
VCAM-1 upregulation were mitigated by SIRT6 over-
expression in ECs, suggesting that SIRT6 negatively 
regulates endothelial cell activation via suppressing the 
expression of adhesion molecules. The NF-ƙB 
transcriptional factor drives the expression of 
chemokines and adhesion molecules, such as ICAM-1 
and VCAM-1, which recruit monocytes to diseased 
endothelium and initiates the development of 
atherosclerosis [63].  One possible explanation for the 
negative regulation of ICAM-1 and VCAM-1 by SIRT6 
might be: SIRT6 deacetylates H3K9 at NF-ƙB target 
genes (ICAM-1 and VCAM-1) promoter and suppresses 
TNF-α-induced ICAM-1 and VCAM-1 expression [39]. 
Our RNA-seq data further provide a transcriptomic 
analysis of potential SIRT6 target genes. One candidate 
gene regulated by SIRT6 is TNFSF4, which is a NF-ƙB-
associated atherosusceptible gene [37]. Our ChIP assays 
show that SIRT6 binds to TNFSF4 gene promoter and 
deacetylates H3K9 at TNFSF4 gene promoter, which 
results in SIRT6-dependent repression of TNFSF4 
transcription in ECs. Whether similar mechanisms also 
control other potential SIRT6 target genes that we have 
identified in our RNA-seq experiments remain to be 
investigated in future studies.  
 
Due to the fact that ApoE -/- mice fed a HFD show 
reduced SIRT6 expression [26, 27], it is of great 
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importance to investigate in future studies whether EC-
specific SIRT6 overexpression will rescue vascular 
inflammation and atherosclerosis development. Also, 
the model we used in this study is SIRT6 
haploinsufficient mice, so the specific contributory roles 
of EC, SMC and macrophage derived SIRT6 in 
atherosclerosis development remains to be investigated 
using individual cell type-specific knockout mice in 
future studies.  
 
In conclusion, our studies identify SIRT6 as a negative 
regulator of endothelial activation and atherosclerotic 
lesion development. Our findings also suggest that 
SIRT6-activating compounds could be potential 
therapeutics in the prevention/treatment of athero-




Mice and diet. Animal procedures used in this study are 
in accord with institutional guidelines and were 
approved by the Institutional Animal Care and Use 
Committee of the University of Rochester Medical 
Center. Mice expressing Cre recombinase under control 
of the EIIa-Cre promoter/enhancer and SIRT6-floxed 
(SIRT6flox/flox) mice [30] were purchased from the 
Jackson Laboratory (Bar Harbor, ME, USA). LoxP 
recombination sites flank exons 2 and 3 of the SIRT6 
gene. To generate SIRT6 total knockout (SIRT6-/-) 
mice, SIRT6flox/flox mice were cross-bred with 
C57BL/6J EIIa-Cre mice. After that, SIRT6+/− males 
were crossed to SIRT6+/− females to obtain SIRT6-/- 
mice. After weaning, male SIRT6+/+, SIRT6+/− and 
SIRT6-/- mice were fed a normal chow diet or high fat 
diet (HFD) (TD.88137, Harlan Teklad) for 12 weeks 
before vascular reactivity analyses. We used both 
genders of mice for experiments involving whole-body 
SIRT6-deficient mice. To generate endothelium-
specific SIRT6 knockout mice (Tie2-Cre/SIRT6flox/flox, 
defined as ecSIRT6-/-), female SIRT6flox/flox mice were 
cross-bred with male C57BL/6J Tie2-Cre mice. Then, 
male Tie2-Cre/SIRT6flox/+ mice were further 
intercrossed with female SIRT6flox/flox mice to obtain 
ecSIRT6-/- mice. Male SIRT6flox/flox littermates were 
used as the control. To determine whether SIRT6 
haploinsufficiency aggravates the development of 
atherosclerosis in ApoE−/− mice, SIRT6+/− males were 
crossed to ApoE−/− females to obtain SIRT6+/−; 
ApoE−/− mice. Male SIRT6+/+; ApoE−/− littermates 
were used as the control.  To accelerate the 
development of atherosclerosis, 8 weeks old 
SIRT6+/−;ApoE−/− and SIRT6+/+;ApoE-/- mice were fed 
a HFD (TD.88137, Harlan Teklad) for 8 weeks before 
endpoint analysis.  
Genotyping of experimental mice. Mice carrying a 
SIRT6 floxed allele were genotyped by PCR using 
primers GF1 (5’-GCTAATGGGAACGAGACCAA-3’) 
and GR1 (5’-ACCCACCTCTCTCCCCTAAA-3’) [30]. 
This primer pair amplifies a 390-bp fragment from the 
wild-type SIRT6 gene and 444 bp from the floxed 
allele. The deletion (Δ) allele of SIRT6 is amplified 
using primers GF1 and GR3 (5’-
GCGTCCACTTCTCTTTCCTG-3’) [30], which 
produces a fragment of 524 bp. The PCR profile was set 
as follows: 94°C, 5 min; 94°C, 20 sec; 60°C, 20 sec; 
72°C, 1 min (35 cycles); 72°C, 5 min; 10°C forever. Tail 
DNA was subject to regular RT-PCR using 2X GoTaq 
Green Master Mix (Promega, Madison, WI, USA). 
Reaction products are separated in 1.5% agarose gel and 
visualized with Image Lab 5.1 software (Bio-rad).  
 
Arterial blood pressure and heart rate measurements. 
Systolic arterial blood pressure (SBP) and heart rate 
(HR) were measured using an automated 6-chamber 
non-invasive tail-cuff plethysmography (BP-2000, 
Visitech System, Apex, NC, USA) [64]. The mice were 
habituated to this procedure for 5 days of training 
before the actual experiments that were performed for 2 
days. Recordings were averaged 20 consecutive 
readings per day after 10 preliminary recordings. 
 
Vascular reactivity experiment. Mouse thoracic aorta 
were dissected and mounted in a four-chamber Multi-
wire Myograph System (DMT-610M, Arhus, Denmark) 
[64-66]. Vascular segments were dissected free of loose 
connective and peri-aortic adipose tissue under 
dissecting microscope (Olympus SZX7), and cut into 
rings of equal length (2 mm). The rest of aorta was used 
for Western blot analysis. Artery segments were 
maintained at 37°C in Krebs physiological saline 
solution (PSS) of the following composition (in mM): 
118.3 NaCl, 4.7 KCl, 2.5 CaCl2, 1.2 MgSO4, 25 
NaHCO3, 1.2 KH2PO4, and 5.5 D-Glucose. PSS was 
pre-warmed at 37°C and saturated with air balanced-5% 
CO2 to maintain a pH of 7.4. Arteries were subject to a 
wake-up protocol by stimulation two times with a 60 
mM-K+ Krebs solution (K-PSS), in which NaCl was 
substituted with KCl of equal molar concentration, for 3 
min each at 10-min intervals. Subsequently, aortic ring 
contraction was induced with phenylephrine (PE, 
Sigma, 10-6 mol/L), and aortic ring relaxation was 
induced with cumulative additions of the endothelium 
dependent vasodilator acetylcholine (Ach, Sigma, 10-9 
to 10-5 mol/L) or NO donor sodium nitroprusside (SNP, 
Sigma, 10-9 to 10-5 mol/L). Vasodilatory responses were 
expressed as percent relaxation relative to PE-induced 
vascular tone, with 100% representing full relaxation to 
basal tension. Force was recorded via a PowerLab 4/30 
system (AD Instruments Ltd., UK) and analyzed using 
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LabChart 7.0 Acquisition System (AD Instruments Ltd., 
UK).  
 
Measurement of serum lipid profile. Mice were fasted 
overnight before blood collection from retro-orbital 
plexus as previously described [67]. Serum was 
prepared and total triglycerides (TG), HDL, and 
LDL/VLDL concentrations were measured using 
commercial colorimetric kits (#K622-100 for TG, 
#K613-100 for HDL and LDL/VLDL; BioVision, 
Milpitas, CA). For sample preparation, 2 μl undiluted 
serum were used for detecting TG level. To detect HDL 
and LDL/VLDL levels, 40 μl mouse serum were mixed 
with 40 μl 2 X Precipitation Buffer. The mixture was 
incubated 10 min at room temperature and then 
centrifuged at 2000 g using bench-top microcentrifuge 
for 10 min. The supernatant (HDL fraction) was 
transferred to new tubes. 10 μl was supernatant was 
used for measuring HDL levels. The precipitates are the 
LDL/VLDL fraction, after another spin at above 
conditions; trace amount of HDL supernatant was 
carefully removed. The resulting pellet was dissolved in 
400 μl PBS. 4 μl was used to measure LDL/VLDL 
levels. The amount of serum used is optimized to ensure 
the final readings fall within the detection limit of the 
kits. Absorbance was measured at 590 nm using a 
Wallac VICTOR™ 1420 Microplate Reader  
(PerkinElmer, Waltham, MA).  
 
Cell culture. Human umbilical vein endothelial cells 
(HUVECs) were obtained from fresh umbilical cord 
veins from normal pregnancies with patients’ informed 
consent [66, 68]. HUVECs were cultured in M200 
medium supplemented with 5% fetal bovine serum 
(FBS), 1% penicillin/streptomycin, 1% L-glutamine, 10 
U/mL heparin and 25 μg/mL endothelial cell growth 
supplement (ECGS). The cells were grown at 37°C in 
humidified 5% CO2 and used for experiments between 
passages three and five. Human monocyte-derived 
THP-1 cells (gifted by Y. Cai) were maintained in 
RPMI 1640 medium supplemented with 10% heat-
inactivated FBS, 2 mM L-glutamine, 100 μg/mL of 
streptomycin and 100 U/mL of penicillin. All reagents 
for cell culture were from Thermo Fisher Scientific 
unless specified otherwise. 
 
RNAi experiments.  HUVECs were transfected at 80% 
confluence with 20 nM SMARTpool ON-TARGETplus 
SIRT6 siRNA (siSIRT6, #L-013306-00-0005) 
(Dharmacon, Lafayette, CO) or with ON-TARGETplus 
Non-targeting Control Pool siRNA (siNC, D-001810-
10-05) in Opti-MEM (Gibco, Grand Island, NY, USA), 
using Lipofectamine 2000 (Invitrogen) [68]. After 4 h 
of transfection, the medium was changed to fresh M200 
complete media, and cells were maintained for 48 h 
before further experiments.  
 
Analysis of atherosclerotic lesions.  En face aorta and 
aortic sinus sectioning were prepared for Oil Red O 
staining as previously described in detail [66, 67, 69]. 
For the en face analysis of the aorta, the Oil Red O 
stained aortas were photographed and captured with 
ProgRes Speed XTcore5 CCD camera (JENOPTIK AG, 
Germany) mounted on a microscope (Leica S8AP0, 
Germany). The pictures presented were a composite of 
4-6 images captured at different regions of the same 
aorta. The total aortic surface area and the lesion area 
were measured by computer-assisted morphometry 
using NIH ImageJ software (http://imagej.nih.gov). The 
ratio of the lesion area to the total area was calculated. 
Quantitative analysis of the total lesion area in aortic 
sinus was also performed with the NIH ImageJ 
software.  
 
Western blot analysis. Whole cell lysates were prepared 
from cultured cells and aorta as described previously 
[66, 68]. For Western blots, total cell lysates (15-20 µg) 
were separated by SDS-PAGE, transferred to 
nitrocellulose membrane (Pall, East Hills, NY) and 
were subsequently blocked in LI-COR blocking buffer 
(LI-COR Biosciences, Lincoln, NE) at room 
temperature for 1 h. Then the blots were incubated 
overnight at 4 °C with appropriate primary antibodies 
listed in Table S6. Then after being washed 3 times with 
1 X Tris buffered saline with 0.1% Tween-20 (TBST), 
membranes were incubated with IRDye® 680RD Goat 
anti-Mouse IgG (H+L) or IRDye® 800CW Goat anti-
Rabbit IgG (H + L) (1:10,000 dilution in 1XTBST; LI-
COR) at room temperature for 30 min. Images were 
visualized by using an Odyssey Infrared Imaging 
System (LI-COR).  
 
Real-time quantitative PCR (qRT-PCR). Total RNA 
was extracted from cultured human ECs and indicated 
mouse tissues using an RNeasy Mini kit (Qiagen) and 
Trizol Lysis Reagent (Invitrogen), respectively [66]. For 
reverse transcription, total RNA was converted into first 
strand complementary DNA (cDNA) using a High-
Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems) following the manufacturer’s instructions. 
Regular genotyping RT-PCR was performed using 2X 
GoTaq Green Master Mix (Promega). Reaction 
products were separated in 1% agarose gel and 
visualized with Image Lab 5.1 software (Bio-rad). 
Quantitative real-time PCR was then performed with a 
Bio-Rad CFX96 Touch Real-Time PCR Detection 
System or Bio-Rad iQ5 real-time PCR thermal cycler, 
using iQ SYBR Green Supermix (Bio-Rad) for relative 
mRNA quantification. The sequences of all the primers 
  
www.impactaging.com                  1074                                          AGING, May 2016, Vol. 8 No.5
used were listed in Table S7. The comparative cycle 
threshold (Ct) method (2−ΔΔCt) [70] was used to 
determine the relative mRNA expression of target genes 
after normalization to housekeeping gene GAPDH or β-
actin.  
 
In vitro monocyte adhesion assay. HUVECs were 
treated with human SIRT6 siRNA (for 48 h) or SIRT6 
adenovirus [21.66] (for 24 h) before stimulation with 
mouse recombinant TNF-α (5 ng/mL, Roche, 
Indianapolis, IN) for 6 h, then THP-1 monocytes were 
added to monolayers of HUVECs and incubated for an 
additional 30 min. Non-adherent THP-1 cells were 
removed by washing three to five times with pre-
warmed serum free M200 media. Attached cells were 
then observed by an inverted microscope Zeiss Axiovert 
40C microscope (magnification: ×10; numeric aperture: 
0.25; Carl Zeiss) using a Canon A640 digital camera 
[66]. The number of monocytes attached to ECs was 
manually calculated using Image Pro-Plus software 
Version 6.2 (Media Cybernetics, Rockville, MD). The 
images presented are shown after Image J adjustment of 
the threshold to label adhered monocytes with red. 
 
Chromatin immunoprecipitation (ChIP) assay.  ChIP 
assays were performed using EZ-Magna ChIPTM A/G 
ChIP kits (#17-10086, EMD Millipore), with slight 
modifications. After treatment, HUVECs (3~4X105 cell 
equivalents per IP) were fixed with 1% formaldehyde 
for 10 min at room temperature by directly adding 37% 
formaldehyde (#252549, Sigma-Aldrich) to the culture 
media to cross-link the DNA-protein complex. Glycine 
(10X) was added to each dish to quench unreacted 
formaldehyde and to terminate cross-linking reaction. 
Next, cells were washed three times with cold 1XPBS 
and harvested by scraping using 1X PBS with 
1XProtease Inhibitor Cocktail II (PIC). After 
centrifugation at 800 g for 5 min at 4°C, cell pellets 
were resuspended in Cell Lysis Buffer with PIC and 
incubated on ice for 15 min with brief vortex every 5 
min. At the end of incubation, cell lysate were passed 
through BD U-100 29G1/2 Insulin Syringes to facilitate 
the release of nuclei. Nuclear pellets were then obtained 
by centrifugation at 800 g for another 5 min at 4°C and 
resuspended in Nuclei Lysis Buffer with PIC. The 
resulting material is sonicated on crushed ice water to 
create chromatin fragments ranging 200~1000 bp in size 
by using Diagenode Bioruptor® UCD-200 Sonication 
System (Denville, NJ) (settings: 2X10 cycles of 30 sec 
pulses with 30 sec rest in between pulses and power 
setting at “High”). Lysates were then centrifuged at 
12,000 g for 10 min at 6°C to pellet the precipitated 
SDS, and incubate with 20 μl fully resuspended Protein 
A/G magnetic beads and ChIP-validated rabbit SIRT6 
[27, 40] and H3K9Ac [40] antibodies at 4°C for 4 h or 
overnight with rotation. Then equal amounts of 
chromatin were incubated overnight with control rabbit 
IgG as negative control. The protein A/G magnetic 
beads bound chromatin was pelleted with  12-tube 
Magnetic Separation Rack (#14654, Cell Signaling), 
followed by washing with Low Salt Wash Buffer, High 
Salt Wash Buffer, LiCl Wash Buffer and TE buffer 
sequentially. Chromatin-associated proteins were then 
digested with 1 µl proteinase K (10 mg/ml) for 2 h at 
62°C with gentle shaking and incubate at 95°C for 10 
min. Chromatin DNA were then purified with spin 
columns provided with the kit. Additional DNA 
purification kits were from Qiagen (QIAquick PCR 
Purification Kit, # 28104, Valencia, CA). Finally, real-
time PCR was performed by using ChIP primers (Table 
S7). The amplification efficiency of PCR primers is 
>90% as calculated from a standard curve generated 
from serially diluted genomic DNA template. PCR 
products are analyzed within the linear amplification 
phase of PCR. To control for variation between ChIP 
fractions, the amount of each promoter region of 
interest in the initial chromatin (Input DNA, 1% unless 
indicated) fraction was used for a normalization factor 
for the number of genome equivalents used in the 
analysis. Input DNA Ct was adjusted from 1% to 100% 
equivalent by subtracting a Ct value of 6.644 or 
Log2100. ChIP-PCR of human GAPDH promoter 
region was used as the positive control for H3K9Ac 
ChIP (Figure S5). Data were presented as a signal 
relative to the total input fraction (%input) using 
comparative cycle threshold (Ct) (2−[Ct(IP)-Ct (input) ) 
method.  
 
RNA sequencing (RNA-seq). RNA was extracted using 
an RNeasy Mini kit (Qiagen, Valencia, CA) per 
manufacturer’s instructions. High-quality RNA 
samples (pre-assessed by Nanodrop 2000) were further 
processed in the Genomics Research Center of the 
University of Rochester. Briefly, RNA quality 
assessed with the Agilent Bioanalyzer (Agilent, 
Santa Clara, CA). The TruSeq RNA Sample 
Preparation Kit V2 (Illumina, San Diego, CA) was 
used for next generation sequencing library 
construction per manufacturer’s protocols. mRNA 
was purified from 100 ng total RNA with oligo-dT 
magnetic beads and fragmented. First-strand cDNA 
synthesis was performed with random hexamer 
priming followed by second-strand cDNA synthesis. 
End repair and 3’ adenylation was then performed 
on the double stranded cDNA. Illumina adaptors 
were ligated to both ends of the cDNA, purified by 
gel electrophoresis and amplified with PCR primers 
specific to the adaptor sequences to generate 
amplicons of approximately 200-500 bp in size. The 
amplified libraries were hybridized to the Illumina 
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single end flow cell and amplified using the cBot 
(Illumina, San Diego, CA) at a concentration of 8 
pM per lane. Single end reads of 100 nt are 
generated for each sample and aligned to the 
organism specific reference genome. The sequencing 
was performed using the Illumina high-throughput 
HiSeqTM 2500. 
 
Gene ontology, pathway enrichment and functional 
annotation clustering analysis. Gene ontology (GO), 
pathway enrichment analysis was performed using the 
Enrichr tools available at the Enrichr Web site 
(http://amp.pharm.mssm.edu/Enrichr/index.html) [33].  
Functional annotation clustering analysis was 
performed using the DAVID Bioinformatics Resources 
6.7 (https://david.ncifcrf.gov/) according to published 
literature [34].  
 
Statistical analysis. Data are presented as means ± SEM 
unless otherwise indicated. Statistical analysis was 
performed using GraphPad Prism Software Version 
5.02 (GraphPad software, La Jolla, CA). Results were 
evaluated by t-test or by one- or two-way analysis of 
variance (ANOVA) when appropriate. When multiple 
comparisons were made, a Bonferroni correction was 
performed for each test. A P value P<0.05 were 
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Figure  S1.  Tissue  distribution  of  SIRT6.  SIRT6  is  expressed  in
multiple mouse  tissues  (C57BL/6J mice, 3 month old) as measured
by qRT‐PCR.  In addition  to  the spleen  (which harbors erythrocytes,
monocytes, B‐ and T‐lymphocytes), endothelial cell‐enriched aortic,
lung  and  brain  tissues  show  the  enrichment  of  SIRT6  gene
expression.  Relative  SIRT6 mRNA  to GAPDH  level  in  skeletal  (S.K.)
muscle was set at 1.0, n = 3.  









Figure  S4.  Silencing  efficiency  of  SIRT6  siRNA  and  over‐
expression  efficiency  of  SIRT6  adenovirus.  Western  blot
analysis of protein expression of SIRT6 in HUVECs transfected with
SIRT6  siRNA  (20 nM,  48 h, A) or  infected with  SIRT6  adenovirus
(M.O.I. 10, 24 h, B), n=4 for panel A and n=3 for panel B.  
  

















































































































either  rabbit  H3K9Ac  or  normal  rabbit  IgG  as  the
immunoprecipitating antibody. Purified DNA was then analyzed by
PCR using  control primers  specific  for  the GAPDH promoter  (166
bp). PCR product was observed  in  the anti‐H3K9Ac ChIP  (lane 3)
but not  in  the normal  rabbit  IgG ChIP  (lane 2). GAPDH promoter
specific DNA was also observed in the Input (lane 1) and not in the
“No  template” PCR  control  (lane 4). Representative blots  from 3
independent experiments. 
Supplementary Table S1. Body weight, systolic blood pressure and heart rate of SIRT6 total
knockout  (SIRT6‐/‐)  and  endothelium‐specific  knockout  (ecSIRT6‐/‐,  Tie2‐Cre;  SIRT6  flox/flox)
mice. Data are presented as Mean±SD, n=8‐15. *P<0.05; ***P<0.001. 
Supplementary  Table  S2.  Analysis  of  progeny  from male  Tie2‐Cre;  SIRT6flox/+ mice  and  female 
SIRT6flox/flox intercross. 
 
Genotypes SIRT6flox/+ SIRT6flox/flox Tie2-Cre; SIRT6flox/+ Tie2-Cre; SIRT6flox/flox 
Number 39 32 35 33 




Lipid profile Sirt6+/+; ApoE-/- (n=7) Sirt6+/-; ApoE-/-(n=8) p Value 
TG (mg/dl) 59.89 ± 5.868 59.36 ± 2.140 0.9295 
HDL-C (mg/dl) 44.56 ± 9.863 
 
88.60 ± 7.077 0.0027 
LDL-C/VLDL-C 
(mg/dl) 
424.1 ± 38.62 352.6 ± 21.72 0.1188 
8 weeks Sirt6+/+; ApoE-/- and Sirt6+/-; ApoE-/- mice were fed a HFD for 8 weeks, then fasted serum 
was collected for detecting lipid levels as described in Method section.  
  
www.impactaging.com                  1080                                          AGING, May 2016, Vol. 8 No.5
Supplementary Table S4. Genes significantly down-
regulated >40% after the infection with SIRT6 
adenovirus for 24 h.  Please browse Full text version to 
see data of this table. 
 
Supplementary Table S5. Genes significantly 
upregulated by 1-fold after the infection with SIRT6 
adenovirus for 24 h.  Please browse Full text version to 








































































































Antibodies Supplier, Cat. No. Dilution Application 






Western blot (mice tissues) 
Western blot (mice tissues) 
ChIP assay 






H3K9Ac Sigma-Aldrich, #H9286 2 µg/ChIP ChIP assay  
ICAM-1 Santa Cruz, #sc-8439 1: 1,000 Western blot 
VCAM-1 Santa Cruz, #sc-1504 1: 1,000 Western blot 
α-Tubulin Sigma, #T5168 1:10,000 Western blot 
GAPDH Millipore, #AB2302 1: 5,000 Western blot 
Rbt IgG Santa Cruz, #sc-2027 2 µg/ChIP ChIP assay 
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Supplementary Table S7. List of primers 
ChIP‐q PCR 
Promoter Sequence (5’-3’) 
GAPDH* Forward: AACAGCAACTCCCACTCTTC 
Reverse: CCTGTTGCTGTAGCCGTATT 
TNFSF4 Forward: GGAAGGAAAGGAGACAAGGATAC 
Reverse: CCCTTTGAGGCAAATTCAATAAAC 
 





Gene Sequence (5’-3’) 
mSirt6 Forward: CGTCTGGTCATTGCAACCT 
Reverse: GAGTCTGCACATCACCTCATC 
mGAPDH Forward: AACAGCAACTCCCACTCTTC 
Reverse: CCTGTTGCTGTAGCCGTATT 
hTNFSF4 Forward: ATCTCCCTGAAGGGCTACTT 
Reverse: 
GTTGACAGACCTGACCTTCTTC 
hGAPDH Forward: GATTCCACCCATGGCAAATTC 
Reverse: CTGGAAGATGGTGATGGGATT 
m, mouse; h, human 
